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Eight infants (two whites and six blacks) with erythrocyte uridine diphosphate galactose-4- 
epimerase (epimerase) deficiency were identified in four newborn screening programs for galac- 
tosemia in the United States. The initial biochemical findings in all cases were elevated blood 
galactose-l-phosphate with normal or only slightly increased blood galactose and normal 
galactose-l-phosphate uridyltransferase (GALT) activity. Epimerase deficiency was confirmed 
in erythrocytes by a two-step enzymatic assay involving fluorometric measurements of NADH 
generated by coupling the uridine diphosphate glucose dehydrogenase reaction to epimerase. 
Seven of the eight infants appeared to be clinically normal at birth and one newborn had 
neonatal jaundice. The infrequent recognition of epimerase deficiency is likely due to the 
methods of newborn screening for galactosemia which are often only for GALT deficiency and 
perhaps also due to incomplete follow-up of increased metabolite levels in newborn blood 
specimens with normal GALT activity. Our results confirm a preliminary report of a high 
frequency of erythrocyte epimerase deficiency in the American black population. 
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Introduction 
There are three inherited disorders of galactose metabolism in man resulting in 
elevation of blood galactose: galactokinase deficiency, galactose- 1 -phosphate 
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uridyltransferase (GALT) deficiency, and uridine diphosphate galactose-4-epimerase 
(epimerase) deficiency [l]. The second of these disorders, GALT deficiency, is usually 
referred to as galactosemia. 
Neonatal screening for galactosemia is performed worldwide. Presently 41 states 
and the District of Columbia in the US include this screening within their newborn 
screening programs; however, there is no uniform approach to this screening. Some 
laboratories use metabolite methods such as the Guthrie inhibition assay [2], the 
Paigen assay [3], the Fujimura method [4], or modification of the latter procedure 
[5-71, which detect accumulation of the metabolites galactose and galactose-l- 
phosphate (Gal-l-P) by galactose dehydrogenase coupling. Others use an enzymatic 
assay for GALT activity, the most common of which is the blood spot assay of 
Beutler and Baluda [8]. Automated analysis of GALT activity from filter paper 
blood specimens has also been employed [9]. Some laboratories use a combination 
of metabolite and GALT activity determinations. In addition to identifying patients 
with GALT deficiency, the metabolite assays can also identify patients with galactoki- 
nase and epimerase deficiencies. 
Galactosemia due to GALT deficiency is the most clinically severe and the most 
frequent of these disorders. It has an occurrence rate of about 1 in 62,000, although 
this varies with different populations [lo]. Galactokinase deficiency is associated 
with cataracts and seems to be very rare. Two types of epimerase deficiency based 
on clinical presentation have been described. One is considered benign with severe 
enzyme deficiency found in erythrocytes and leukocytes and near normal activity in 
liver and cultured skin fibroblasts [11,12]. Cultured lymphoblasts also showed sub- 
stantial epimerase activity, suggesting an unstable mutant epimerase [13]. The other 
is associated with severe clinical manifestations similar to galactosemia with enzyme 
deficiency demonstrated in erythrocytes and cultured skin fibroblasts [14,15]. 
A number of cases with the benign form of epimerase deficiency have been reported 
in Switzerland [12] and Japan [16]. Herein we report the first cases of what appears 
to be the benign form of epimerase deficiency detected in four state screening 
programs in the United States. This study confirms the preliminary report of a high 
frequency of epimerase deficiency in the American black population [ 171. 
Material and Methods 
All reagents for the assay of UDPGal-Cepimerase were from Sigma Chemical 
Co. (St. Louis, MO, USA). These include uridine diphosphate galactose (UDPGal), 
uridine diphosphate glucose (UDPGlc), nicotinamide adenine dinucleotide oxidized, 
nicotinamide, glycine, and UDPGlc dehydrogenase (Sigma U5500). 
Blood samples of 2-5 ml were obtained from 25 normal infants under 4 months 
of age, 27 normal adults and eight infants suspected of epimerase deficiency on the 
basis of elevated levels of Gal-l-P and normal GALT activity found by newborn 
screening. Whenever possible, blood samples were also obtained from the parents 
of the probands. The blood was collected in sodium heparinized tubes. The plasma 
and the buffy coat were removed after centrifugation and the erythrocytes were 
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washed three times with equal volumes of 0.9 g% NaCl. Following the final centrifu- 
gation, the saline was completely removed and the packed cells were immediately 
frozen. Epimerase was found to be stable in the frozen state for at least 3 days. On 
the othe:r hand, epimerase is not stable at room temperature. All blood samples were 
sent frozen to the Biochemical Genetics Laboratory at Childrens Hospital Los 
Angeles. 
Prior to the enzyme assay, the red cells were thawed and 0.5 ml of the hemolysate 
(100%) ‘was added to 0.5 ml of 0.02 M nicotinamide. Nicotinamide serves to inhibit 
NADase which otherwise reduces the epimerase activity [18]. To ensure complete 
hemolysis, the mixture was frozen and thawed three times in an alcohol-dry ice bath. 
The principle of the epimerase assay is based on the following enzyme coupled 
reactiorrs which are carried out separately: 
UDPGal NAD: 
(Epimerase) UDPG1c (1) 
UDPGlc + 2NAD + (UDPG,carOrogenasej UDPGA + 2NADH + 2H + 
UDPGA designates uridine diphosphate glucuronic acid. 
The amount of NADH generated in the second reaction is measured fluoromet- 
rically and is proportional to the epimerase activity in the first reaction. 
All assays were carried out in duplicate. For the first reaction, 0.1 ml of the 50% 
hemolysate in 0.02 M nicotinamide was incubated with 0.05 ml of 5 mM UDPGal, 
0.1 ml of 1 M glycine buffer (pH 8.7) and 0.05 ml of 0.01 M NAD. For the blank, 
water was substituted for UDPGal. Samples were incubated at 37°C for 20 min, 
heated at 100°C for 3 min, cooled in an ice bath and finally centrifuged at room 
temperature, 1000 x g for 5 min to obtain a clear supernatant. 
The second reaction contained 1.0 ml of 0.1 M glycine buffer (pH 8.7) 0.1 ml of 
0.01 M NAD, 0.03 ml of supernate from the first reaction and 25 ul of UDPGlc 
dehydrogenase (corresponding to 0.005 U). Samples were incubated at room temper- 
ature fo:r a period of 60-80 min and maximum fluorescent readings were recorded 
in a Turner fluorometer model 112 with primary filter No. 7-60 and secondary filter 
No. 48 and a setting of 1 x . A standard curve was generated by running the second 
reaction using dilutions of a 0.5 mM UDPGlc solution. Under our experimental 
conditions, 10 nmol of UDPGlc gave a fluorescent reading of 72 units. Epimerase 
activity :is expressed as umols UDPGlc formed/h/g Hb. 
Results 
Erythrocyte UDPGal-4-epimerase activities in normal individuals are shown in 
Table 1. As a group, the activity is higher in the infants under 4 months of age than 
in adults (PC 0.001, Student’s t test). 
All of the eight infants with erythrocyte epimerase deficiency detected by newborn 
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TABLE 1 
Erythrocyte UDPGal-4-epimerase activities in normal controls 
Normal controls No. Mean SD Range 
Infants (2 wks to 4 mos) 25 23.9 4.7 14.8-30.9 
Adults 21 18.4 3.1 14.3-26.3 
Epimerase activity expressed as pmols/h/g Hb. 
screening for galactosemia showed elevated ‘total galactose’ (galactose and/or 
galactose-l-phosphate) values of over 20 mg/dl and normal GALT activity by the 
spot enzyme assay (Table 2). The deficiency in epimerase activity ranged from 0 to 
3.8 units (normal mean activity is 23.9f4.7 units). Six of the eight infants with 
epimerase deficiency are black while the remaining two are Caucasian. The deficiency 
was found in both males and females. All but one were known or reported to be 
clinically normal during the neonatal period. The exception is an infant (CR) who 
had neonatal jaundice which subsequently resolved. Patient LE has a congenital 
cardiac lesion (venticular septal defect) and was discovered to have thrombocyto- 
penia at age 2 years. She is now under study for a possible blood dyscrasia. It is 
unclear whether this is related to the epimerase deficiency. 
Figure 1 shows the pedigree analyses of the five families in which the parents were 
also studied. The results are consistent with autosomal recessive inheritance with the 
obligate carriers having about l/2 normal values. For the black family, HA, two 
children and their father were found to have very low epimerase activity. We cannot 
clearly interpret the result in the father for family WA. It appears that there is a 
spectrum of enzyme deficiency among the blacks which suggests the possibility of 
variant forms. 
TABLE 2 
Erythrocyte UDPGal-Cepimerase deficiency 






























36.8 Gal deh/Alk phos 
31.0 Gal deh/Alk phos 
24.3 Gal deh/Alk phos 
54.4 Gal deh/Alk phos 
22.8 Gal deh/Alk phos 
Epimerase activity expressed as pmols/h/g Hb. 
Gal + Gal- 1-P concentration expressed as mg/dl. 
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Fig. 1. Pedigree analysis of erythrocyte UDPGal-Cepimerase deficiency. 
Discussion 
The :first case of epimerase deficiency in man was reported by Gitzelmann in 
Switzerland in a newborn screening program for galactosemia [19]. Microbiological 
assay revealed increased levels of total galactose (galactose and/or Gal-l-P) in the 
newborn blood sample. Subsequent follow-up study when the patient was on a 
regular diet of cow’s milk showed erythrocyte Gal-l-P levels between 14 and 
18.5 mg!dl. The infant was healthy. Following this original publication, Gitzelmann 
identified several more patients, including three newborns, one older sibling and 
three women over 60 years of age in family studies [12]. All were healthy despite the 
absence of epimerase activity in both red and white blood cells. However, epimerase 
activity in cultured skin fibroblasts and liver was near normal. 
Fujimura et al. developed a new mass screening for epimerase deficiency in Japan 
[20] and the first case from Japan was reported in 1980 [16]. The levels of erythrocyte 
Gal-l-P in this case varied from 15 to 42 mg/dl in RBC. Subsequently another case 
of epimerase deficiency was reported from Japan [21]. However, erythrocyte epi- 
merase activity in this child was 7.5% of the normal level, which is not as deficient 
as the cases reported by Gitzelmann et al. [12]. Analysis of galactose metabolites in 
blood by thin layer chromatography showed the accumulation of either Gal-l-P or 
UDPGal or both. It is of interest that the UDPGal levels in the erythrocytes of our 
two patients (patient LE and another patient not included in Table 2) determined 
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by our enzymatic assay were 2-3-times that of the normal controls. Another case 
of erythrocyte epimerase deficiency reported by Bowling et al. in Australia [22] had 
increased erythrocyte Gal-l-P (10,000 nmol/g Hb vs. normal level of < 170 nmol/g 
Hb) and only slightly increased plasma galactose (70 nmol/l vs. normal level of 
< 40 nmol/l). Thus, in epimerase deficiency Gal-l-P is much more increased than 
galactose, which may show only a slight elevation. Gitzelmann modified the original 
Paigen test by the addition of alkaline phosphatase to release galactose from Gal- 
l-P so that epimerase deficiency can be detected [23]. 
Even though galactosemia screening in the US has been performed for over 2 
decades, only three cases of erythrocyte epimerase deficiency have been reported 
[17]. In the present study we include two of these three patients and additional 
patients identified in other screening programs. Accumulation of Gal-l-P to the level 
of 20 mg% or higher seemed to be the most consistent finding when the infants were 
on normal lactose-containing formula or breast feedings. Since all cases had normal 
transferase activity, these cases would have been missed if the primary screening test 
for galactosemia was based on GALT activity alone, such as the spot enzyme assay 
of Beutler and Baluda [8]. Since many programs in the US use this screening 
approach, it is likely that epimerase deficiency is far more frequent than would be 
suggested by the few cases we are reporting. 
So far seven of these eight children with erythrocyte epimerase deficiency are 
clinically normal in follow-up studies, unlike the two cases of epimerase deficiency 
which presented with clinical problems somewhat similar to those of classical galac- 
tosemia [14,15]. It is of interest that both of these latter patients are of Pakistani 
ethnic background. It is possible that the blood dyscrasia in one of our cases is 
related to the epimerase deficiency as she is the only child among the eight we are 
reporting who had no detectable epimerase activity. This is currently under investiga- 
tion. If there is a relationship, this would represent a new finding in epimerase 
deficiency. This patient has none of the clinical features described for the Pakistani 
patients. Epimerase assay in cultured skin fibroblasts would be helpful to establish 
the extent of the enzyme deficiency. At this time we are not aware of any cases of 
epimerase deficiency with severe clinical manifestations detected through newborn 
screening programs for galactosemia. In addition to the findings of accumulated 
Gal-l-P, UDPGal levels in the erythrocytes of the two Pakistani patients were also 
elevated. 
In agreement with Gitzelmann and others [12,16,21], it seems that erythrocyte 
epimerase deficiency is an inherited autosomal recessive trait. The spectrum of 
enzyme deficiency in red cells and in other tissues suggests, however, that there are 
at least several mutations in the gene that produce this deficiency for epimerase. 
Mitchell et al. suggested that the enzyme deficiency in the benign form might be due 
to the presence of an unstable variant [13]. So far the gene for epimerase in man 
has not been molecularly characterized, although it has been localized to the short 
arm of chromosome 1 [24]. 
The present study confirms the likelihood that erythrocyte epimerase deficiency 
has a relatively high frequency in the black population. Based on the Maryland 
study [17], the frequency of epimerase deficiency in blacks has been estimated at 
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approx. l/8,000 to l/12,000. In Mississippi with a population equally divided between 
blacks and Caucasians, only blacks so far have been found to have epimerase 
deficiency. Following the completion of this study, nine more cases of erythrocyte 
epimerase deficiency have been identified. These include four from Maryland, three 
of which are in blacks, and one in a Pakistani/Caucasian infant; four from Mississippi, 
all of whom are black, and the remaining one from Michigan who is also black. 
It is of interest that the prevalence of mutants of all three enzymes of the galactose 
metabolic pathway (galactokinase, GALT and epimerase) differ between blacks and 
caucasi,ans. A galactokinase in blacks with lower activity than normal has been 
described [25] and the ‘Negro variant’ of GALT deficiency (galactosemia) with 
residual liver activity is well known [26]. Now epimerase deficiency can be included 
in this group. With respect to the epimerase activity which is affected by NADase 
in the in vitro assay, NADase deficiency in blacks has also been reported [27]. The 
significance of these mutants in the American black population is not yet known. 
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